


Paranimf



March 23rd, 2015

Symposium on
advances about
CART19 approaches
... and more

Local organizers:

Manel Juan. Immunology. CDB. Hospital Clínic.

Julio Delgado. Hematology. ICMHO. Hospital Clínic.

Susana Rives. Pediatric Hematology. Hospital San Joan de Déu.

Anna Boronat. Institut d'Investigacions Biomèdiques August Pi i Sunyer.

Instituto de Salud Carlos III (ISCIII) & Fondo Europeo de Desarrollo Regional (FEDER):
PI13/00676; PIE13/00033 ; PICIS14/00122

Main sponsorship:



Secretary, registration and information:

Eva Palacios

Tel. +34.93.203.13.18

evapalacios@academia.cat

Registrations: <http://www.cart19.org>

Early: 25 € (until February 28) Late: 50 € (until March 19)

Records strictly limited to the capacity of the auditorium!!



Venue:

Paranimf (Auditorium)

School of Medicine,
Barcelona University (UB)

Hospital Clínic

c/ Casanova 143

08036 BARCELONA, Spain.



Monday, March 23rd, 2015

09:00 – 09:05 Welcome and presentation of the symposium.

Dr. Josep M Piqué (General Director of Hospital Clínic) /

Dr Aura Mira (Director of CDB) /

Dr. Manel Juan (chairman)

09:05 – 10:30 **Table 1: B-cell lymphoproliferative disorders (BLD) and CD19**

Dr. Josep Maria Ribera / Dr. Jordi Yagüe

09:10 – 09:30 CD19 as a key molecule for B-cells.

Dr. Pablo Engel, Univ. Barcelona – IDIBAPS, Barcelona

09:30 – 09:50 Prognosis and treatment of relapsed/refractory non-Hodgkin B-cell lymphoma.

Dr. Armando López-Guillermo, Hospital Clínic – IDIBAPS, Barcelona

09:50 – 10:05 Present and future of Chronic Lymphocytic Leukemia (CLL) clinical management.

Dr. Julio Delgado, Hospital Clínic - IDIBAPS, Barcelona.

10:05 – 10:20 Present and future of pediatric Acute Lymphoblastic Leukemia (ALL) clinical management.

Dr. Susana Rives, Hospital Sant Joan de Deu, Barcelona,

10:20 – 10:30 **Questions and discussion.**

10:30 – 10:45 Coffee break

10:45–12:45 **Table 2: Immunological bases of CART19 treatment as a real Cell Adoptive Cancer Immunotherapy (CACIT).**

Dr. Manel Juan / Dr. Pablo Menéndez

10:45 – 11:05 Overview CACIT in Cancer.

Dr. Daniel Benítez, CEK. CIBERehd, Barcelona, Spain

11:05 – 11:35 CACIT from hematologic diseases to solid tumours.

Dr. James N Kochenderfer, NCI, Washington, USA.

11:35 – 12:05 CART19 present and future.

Dr. Carl H June, UPenn, Philadelphia, USA.

12:05 – 12:30 **Questions and discussion.**

12:30 – 14:00 Working lunch time

14:00 – 16:15 **TABLE 3: Developing a T-cell immunotherapy trial**

Dr. Josep M^a Canals / Dr. Javier Briones

14:00 – 14:25 Regulatory aspects for cell immunotherapy in Europe.

Dr. Esteve Trias, Adv Therap Hospital Clínic – Banc Sang i Teixits, Barcelona.

14:25 – 14:50 Investigator Initiated Clinical Trials (IIT) of Advanced Therapy Medicinal Products in Spain.

Dr. Felipe Prosper, Director of Hematology and Cell Therapy. Universidad de Navarra. Spain.

14:50 – 15:20 How to develop and monitoring CART19 trials.

Dr. Bruce Levine, UPenn, Philadelphia, USA.

15:20 – 15:50 CTL19 trial from Novartis; present and future.

Dr. Alfonso Quintas-Cardama, Global Clinical Leader CTL019 Novartis, Basel. Switzerland

15:50 – 16:15 **Questions and discussion.**

16:15 – 16:30 Coffee break

16:30 – 18:50 **TABLE 4: Clinical management of CART19 patients**

Dr. Julio Delgado / Dr. Susana Rives

16:30 – 17:00 Treating adults with CART19

Dr. David Porter, UPenn, Philadelphia, USA

17:00 – 17:30 Treating children with CART19

Dr. Stephan A Grupp, Children Hospital of Philadelphia, Philadelphia, USA

17:30 – 18:00 2^{ary} effects in the management of CARs treatments

Dr. Renier Brentjens, Memorial Sloan Kettering Cancer Center, NY, USA

18:00 – 18:30 Experience of developing an European CAR trial

Dr. Martin Pule, UCL Institute of Child Health Great Ormond Street Hospital

18:30 – 18:50 **Questions and discussion.**

18:50 – 19:00 Conclusions and closing event

Dr. Francesc Cardellach (Dean of School of Medicine Univ.Barcelona) /

Dr. Josep M Campistol (Medical Director) / **Dr. Manel Juan** (chairman)